Cardiovascular health, heart failure, atherosclerosis, and cardiac research
733 articles
Ten trials support GLP-1 drugs' cardiovascular benefits, but a new model cannot reliably show which works best or how protection changes over time.
A completed phase 2 trial tested EGCG for cardiac light-chain amyloidosis, but the supplied abstract provides no results on benefits or safety.
An eight-week study links daily avocado and mango to better artery function without weight gain. Blood pressure findings were strongest in men.
A study of nearly 486,000 adults links regular tea drinking to fewer vascular diseases. Black tea looked stronger than green, and very hot tea may backfire.
Combining GLP-1 and SGLT2 drugs was linked to lower mortality and fewer heart failure hospitalizations after pacemaker implantation in diabetes.
UC San Diego researchers found a Ral–cathepsin A pathway that depletes liver LDL receptors, and an inhibitor already safety-tested in humans lowered LDL in mice.
A federally commissioned analysis finds that two daily drinks bring a 1 in 25 lifetime risk of alcohol-related death, with no significant overall health benefit.
A large laboratory map links KCNQ1 gene changes to abnormal heart rhythms and could help clarify uncertain genetic test results.
A review links aging artery cells, chronic inflammation, and altered gene regulation to plaque buildup—and explores experimental treatments.
A mechanistic tour of ApoB particle assembly, endothelial entry, proteoglycan retention, and the genetic and trial evidence that cardiovascular benefit tracks absolute ApoB reduction. Includes how each class of drug acts on the pathway.
A study of 500 adults links higher TMAO to higher blood pressure, with significant associations in men and adults 60 or older. Causation remains unproven.
Follow a single ApoB particle from assembly in the liver to clearance or entrapment in the artery wall. Along the way you'll see why particle count tracks risk and where diet, exercise, and drugs actually act.
